Digoxin: A Benchmark Na+/K+ ATPase Pump Inhibitor for Heart Failure and CHIKV Research

Executive Summary: Digoxin is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased cardiac contractility and is a gold-standard tool in heart failure and arrhythmia research (APExBIO, B7684). It exerts potent, dose-dependent antiviral effects against chikungunya virus (CHIKV) in cell models at 0.01–10 μM concentrations (see Digoxin: Cardiac Glycoside for Heart Failure & Antiviral ...). Digoxin is highly soluble in DMSO (≥33.25 mg/mL), but insoluble in water and ethanol, requiring careful preparation for experimental use. In preclinical canine models, intravenous doses of 1–1.2 mg improve cardiac output and decrease right atrial pressure. APExBIO supplies Digoxin with purity >98.6%, supported by HPLC, NMR, and MSDS documentation, ensuring reproducibility for translational research (Biomedicine & Pharmacotherapy 192 (2025) 118665).

Biological Rationale

Digoxin is a prototype cardiac glycoside derived from Digitalis species. It is widely utilized to elucidate mechanisms of cardiac contractility modulation via the Na+/K+-ATPase signaling pathway. The inhibition of Na+/K+-ATPase increases intracellular sodium, indirectly raising calcium levels through the sodium-calcium exchanger. This enhances myocardial contractility (positive inotropy). Digoxin's clinical and preclinical relevance extends to heart failure, arrhythmia, and more recently, antiviral research due to its ability to impair viral entry and replication. Its use in animal models, including canine congestive heart failure, provides a translational bridge to human cardiovascular and infectious disease studies (Digoxin as a Translational Catalyst: Mechanistic Insight ...). This article extends previous mechanistic and workflow-focused discussions by detailing verifiable pharmacodynamic and antiviral benchmarks for Digoxin.

Mechanism of Action of Digoxin

Digoxin binds to and inhibits the membrane-bound Na+/K+-ATPase enzyme. This pump is essential for maintaining electrochemical gradients of sodium and potassium ions across the cell membrane. Inhibition leads to increased intracellular sodium concentration. This, in turn, reduces the activity of the sodium-calcium exchanger, causing accumulation of intracellular calcium. Elevated calcium enhances the contractile force in cardiac myocytes. In parallel, inhibition of the Na+/K+-ATPase impacts cellular signaling pathways involved in arrhythmogenesis and may modulate viral replication machinery, as observed in CHIKV-infected cells. The mechanistic action is highly dose-dependent and cell-type specific, necessitating quantitative validation in target models.

Evidence & Benchmarks

• Digoxin inhibits Na+/K+-ATPase activity in vitro at nanomolar concentrations, resulting in increased intracellular sodium and enhanced contractility (see Biomedicine & Pharmacotherapy 192 (2025) 118665).
• In canine models of congestive heart failure, intravenous Digoxin (1–1.2 mg) increases cardiac output and reduces right atrial pressure within 30 minutes post-administration (internal article summary).
• Digoxin demonstrates dose-dependent inhibition of chikungunya virus infection in U-2 OS, primary human synovial fibroblasts, and Vero cells at concentrations from 0.01 to 10 μM, with significant reduction in viral replication observed at 37°C in standard cell culture conditions (internal article summary).
• APExBIO's Digoxin (B7684) is supplied at >98.6% purity, verified via HPLC and supported by NMR and MSDS documentation, ensuring batch-to-batch reproducibility (product page).
• Digoxin is soluble at ≥33.25 mg/mL in DMSO but insoluble in water and ethanol, requiring immediate use of prepared solutions for experimental accuracy (APExBIO).

Applications, Limits & Misconceptions

Digoxin is a foundational tool in cardiovascular disease research, including studies of heart failure, arrhythmia, and cardiac contractility modulation. Its robust inhibition of the Na+/K+-ATPase pump offers a controllable platform for dissecting ion transport and signal transduction. In virology, Digoxin's ability to inhibit CHIKV replication in various human and primate cell lines has opened new avenues for antiviral agent screening (Digoxin in Advanced Cardiovascular and Antiviral Research...). This article clarifies recent advances by providing quantitative antiviral benchmarks and explicit solubility parameters, updating prior narrative reviews. However, Digoxin's effects are dose-dependent and may vary across species and cell types, requiring careful titration. Misconceptions persist regarding its solubility and direct antiviral spectrum—see below.

Common Pitfalls or Misconceptions

• Water and Ethanol Solubility: Digoxin is insoluble in water and ethanol; DMSO is required for stock solution preparation.
• Long-term Storage: Digoxin solutions should be used immediately after preparation. Long-term storage (>24 hours) can lead to degradation and loss of potency.
• Antiviral Specificity: While effective against CHIKV, Digoxin’s antiviral activity has not been universally validated against other RNA viruses.
• Dose-Response Variability: The effective concentration for Na+/K+-ATPase inhibition and viral suppression varies by cell line and assay conditions.
• Clinical Extrapolation: Preclinical results in animal models or cell culture do not guarantee identical outcomes in human therapeutics.

Workflow Integration & Parameters

For experimental use, Digoxin is best dissolved in DMSO at concentrations ≥33.25 mg/mL. For cell-based assays, dilution in culture medium is recommended, keeping final DMSO concentration below cytotoxic thresholds (typically ≤0.1%). Solid Digoxin should be stored at room temperature, protected from moisture and light. Solutions must be prepared fresh to maintain integrity. Quality documentation includes HPLC, NMR, and MSDS, supporting regulatory and reproducibility requirements. For animal studies, dosing parameters should faithfully replicate published benchmarks (e.g., 1–1.2 mg IV in canine heart failure models). APExBIO’s B7684 kit provides detailed QC data and batch verification. Digoxin’s integration into cardiac and virology research workflows streamlines experimental reproducibility, aligning with best-practice guidelines (Digoxin at the Translational Nexus...—this article delivers updated benchmarks and explicit solubility guidance beyond prior protocol summaries).

Conclusion & Outlook

Digoxin remains a gold-standard Na+/K+ ATPase pump inhibitor and cardiac glycoside for heart failure, arrhythmia, and antiviral research. As supplied by APExBIO, its high purity and robust documentation ensure reproducibility across diverse models. Quantitative solubility, dosing, and mechanistic benchmarks support its continued use as a translational research catalyst. Future research should refine cell-type specific dose-response relationships and expand validation across novel viral models. The Digoxin (B7684) kit from APExBIO is positioned as a reproducible, quality-controlled tool for mechanistic and translational studies in cardiovascular and infectious disease research.